SCHEMBL3789228

SCHEMBL3789228

CCCC(=O)Nc1ccc(C(=O)OC)cc1C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.57
ALDH1A1 P00352 6/20 0.53
KDM4E B2RXH2 3/20 0.53
HSD17B10 Q99714 2/20 0.53
HPGD P15428 2/20 0.53
TP53 P04637 1/20 0.52
THRB P10828 1/20 0.52
L3MBTL1 Q9Y468 3/20 0.52
MAPT P10636 3/20 0.52
POLB P06746 1/20 0.51
GAA P10253 1/20 0.51
LMNA P02545 2/20 0.49
KDR P35968 2/20 0.48
PKM P14618 1/20 0.48
TSHR P16473 1/20 0.48
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
HTT P42858 1/20 0.47
HDAC3 O15379 1/20 0.47
HDAC4 P56524 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29195725 0.90 SMN1; SMN2 (0.56) SMN1; SMN2ALDH1A1KDM4ETP53THRB
SCHEMBL24100464 0.88 SMN1; SMN2 (0.60) SMN1; SMN2ALDH1A1KDM4EHSD17B10HPGD
SCHEMBL6699180 0.85 KDM4E (0.59) SMN1; SMN2ALDH1A1KDM4ETP53THRB
SCHEMBL7311864 0.85 TP53 (0.55) SMN1; SMN2ALDH1A1KDM4EHPGDTP53
SCHEMBL19306009 0.84 ALDH1A1 (0.65) SMN1; SMN2ALDH1A1KDM4EHSD17B10HPGD
SCHEMBL21674083 0.84 SMN1; SMN2 (0.58) SMN1; SMN2ALDH1A1KDM4EHSD17B10HPGD
SCHEMBL23045052 0.84 POLB (0.56) SMN1; SMN2ALDH1A1KDM4EHPGDTP53
SCHEMBL1479187 0.83 SMN1; SMN2 (0.53) SMN1; SMN2ALDH1A1KDM4EHSD17B10HPGD
SCHEMBL4827444 0.83 SMN1; SMN2 (0.53) SMN1; SMN2ALDH1A1KDM4EHSD17B10HPGD
SCHEMBL14513124 0.82 ALDH1A1 (0.77) ALDH1A1KDM4EHSD17B10HPGDL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112441984-B Benzimidazole-substituted phenyl n-butyramide-based compound and preparation method thereof 上海特化医药科技有限公司 2024-04-19 CN claimed
CN-111925299-A Continuous flow method for synthesizing 3-methyl-4-butyryl-5-nitrobenzoic acid methyl ester and reaction device thereof 浙江金立源药业有限公司 2020-11-13 CN claimed
CN-103319415-B Production process of 2-n-propyl-4-methyl-6 (1-methylbenzimidazole-2-yl) -benzimidazole HAIMEN CITY CHEMGOO PHARMA CO LTD 2015-04-29 CN claimed
CN-103319415-A Production process of 2-n-propyl-4-methyl-6 (1-methylbenzimidazole-2-yl) -benzimidazole HAIMEN CITY CHEMGOO PHARMA CO LTD 2013-09-25 CN claimed
CN-1184194-C Method for producing n-butyryl-4-amino-3-methyl-methyl benzoate and the novel compound n-(4-bromine-2-methylphenyl)-butanamide BAYER AG (DE) 2005-01-12 CN claimed
EP-1268400-B1 METHOD FOR PRODUCING N-BUTYRYL-4-AMINO-3-METHYL-METHYL BENZOATE AND THE NOVEL COMPOUND N-(4-BROMINE-2-METHYLPHENYL)-BUTANAMIDE BAYER CHEMICALS AG (DE) 2004-08-11 EP claimed
US-20040030183-A1 Method for producing N-butyryl-4-amino-3-methyl-methyl benzoate and the novel compound N-(4-bromo-2-methylphenyl)butanamide RODEFELD LARS (DE) 2004-02-12 US claimed
US-6620962-B2 Reacting toluidine and butyryl chloride; then bromination; using palladium catalyst BAYER AKTIENGESELLSCHAFT (DE) 2003-09-16 US claimed
CN-1419535-A Process for producing N-butyryl-4-amino-3-methyl-benzoic acid methyl ester and novel compound N- (4-bromo-2-methylphenyl) butyramide BAYER AG (DE) 2003-05-21 CN claimed
US-20030065211-A1 Method for producing n-butyryl-4-amino-3-methyl-methyl benzoate and the novel compound n-(4-bromine-2-methylphenyl)-butanamide LANXESS DEUTSCHLAND GMBH (DE) 2003-04-03 US claimed
CN-112441984-B Benzimidazole-substituted phenyl n-butyramide-based compound and preparation method thereof 上海特化医药科技有限公司 2024-04-19 CN disclosed
WO-2021037127-A1 BENZIMIDAZOLE SUBSTITUTION-BASED PHENYL N-BUTYRAMIDE COMPOUND AND PREPARATION METHOD THEREFOR 上海特化医药科技有限公司 2021-03-04 WO disclosed
CN-111925299-A Continuous flow method for synthesizing 3-methyl-4-butyryl-5-nitrobenzoic acid methyl ester and reaction device thereof 浙江金立源药业有限公司 2020-11-13 CN disclosed
CN-103319415-B Production process of 2-n-propyl-4-methyl-6 (1-methylbenzimidazole-2-yl) -benzimidazole HAIMEN CITY CHEMGOO PHARMA CO LTD 2015-04-29 CN disclosed
CN-103319415-A Production process of 2-n-propyl-4-methyl-6 (1-methylbenzimidazole-2-yl) -benzimidazole HAIMEN CITY CHEMGOO PHARMA CO LTD 2013-09-25 CN disclosed
US-20030065211-A1 Method for producing n-butyryl-4-amino-3-methyl-methyl benzoate and the novel compound n-(4-bromine-2-methylphenyl)-butanamide LANXESS DEUTSCHLAND GMBH (DE) 2003-04-03 US disclosed
US-20030065211-A1 Method for producing n-butyryl-4-amino-3-methyl-methyl benzoate and the novel compound n-(4-bromine-2-methylphenyl)-butanamide LANXESS DEUTSCHLAND GMBH (DE) 2003-04-03 US disclosed
EP-1268400-A2 METHOD FOR PRODUCING N-BUTYRYL-4-AMINO-3-METHYL-METHYL BENZOATE AND THE NOVEL COMPOUND N-(4-BROMINE-2-METHYLPHENYL)-BUTANAMIDE Bayer Aktiengesellschaft (DE) 2003-01-02 EP disclosed
WO-2001072690-A3 METHOD FOR PRODUCING N-BUTYRYL-4-AMINO-3-METHYL-METHYL BENZOATE AND THE NOVEL COMPOUND N-(4-BROMINE-2-METHYLPHENYL)-BUTANAMIDE BAYER AG (DE) 2002-02-28 WO disclosed
WO-2001072690-A2 METHOD FOR PRODUCING N-BUTYRYL-4-AMINO-3-METHYL-METHYL BENZOATE AND THE NOVEL COMPOUND N-(4-BROMINE-2-METHYLPHENYL)-BUTANAMIDE BAYER AKTIENGESELLSCHAFT (DE) 2001-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030065211-A1 Method for producing n-butyryl-4-amino-3-methyl-methyl benzoate and the novel compound n-(4-bromine-2-methylphenyl)-butanamide GABBR2, BBOX1, GABRB3 SMN1; SMN2 2334/4885ALDH1A1 1000/4885KDM4E 98/4885
US-20040030183-A1 Method for producing N-butyryl-4-amino-3-methyl-methyl benzoate and the novel compound N-(4-bromo-2-methylphenyl)butanamide BRD4, GABRB3, GABBR2 SMN1; SMN2 961/4885ALDH1A1 1636/4885KDM4E 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.